Liqun Zhou
About
Research
Publications
2025
Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering
Tang K, Zhou L, Tian X, Fang S, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Kim H, Luo Z, Xin S, Lin S, Park D, Yang L, Zhang Y, Suzuki K, Majety M, Ling X, Lam S, Chow R, Ren P, Tao B, Li K, Codina A, Dai X, Shang X, Bai S, Nottoli T, Levchenko A, Booth C, Liu C, Fan R, Dong M, Zhou X, Chen S. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nature Biomedical Engineering 2025, 9: 1290-1308. PMID: 40114032, PMCID: PMC12360953, DOI: 10.1038/s41551-025-01371-2.Peer-Reviewed Original ResearchKnock-In MiceBone marrow-derived dendritic cellsCD8+ T cellsNon-viral delivery vehiclesAdeno-associated virusDisease modelsCD4+Dendritic cellsC57BL/6 backgroundT cellsConstitutive expressionB cellsLipid nanoparticlesEx vivoGenome editingMiceMultiplex genome engineeringROSA26 locusGene interaction networksMultiplex genome editingLiver tissueTargeted genome editingDiseaseDelivery vehiclesCRISPR RNA
2024
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
Bai Z, Feng B, McClory S, de Oliveira B, Diorio C, Gregoire C, Tao B, Yang L, Zhao Z, Peng L, Sferruzza G, Zhou L, Zhou X, Kerr J, Baysoy A, Su G, Yang M, Camara P, Chen S, Tang L, June C, Melenhorst J, Grupp S, Fan R. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 2024, 634: 702-711. PMID: 39322664, PMCID: PMC11485231, DOI: 10.1038/s41586-024-07762-w.Peer-Reviewed Original ResearchChimeric antigen receptorChimeric antigen receptor T cellsT cellsIL-4CAR T-cell dysfunctionChimeric antigen receptor T-cell productsCAR-T cell persistenceProteomic profiling of seraCAR-T cellsT cell persistenceT-cell therapyLong-term remissionT cell dysfunctionCAR-T productsType 2 cytokinesAntigen-specific activationT cell productionAssociated with patientsType 2 cellsDysfunctional subsetPotential therapeutic strategyCellular immunotherapyLeukemia remissionPatients relapseType 2 functionsCAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology 2024, 21: 1089-1108. PMID: 39134804, PMCID: PMC11442786, DOI: 10.1038/s41423-024-01207-0.Peer-Reviewed Original ResearchCAR-natural killerCAR-T cellsCAR-TSolid tumorsHematologic malignanciesCell therapyChimeric antigen receptor (CAR)-T cell therapyImmuno-suppressive tumor microenvironmentCAR-T cell therapyCellular cancer immunotherapyRelapsed/refractory hematologic malignanciesCAR-NK cellsTumor traffickingAdoptive immunotherapyCell immunotherapyCellular immunotherapyCancer immunotherapyImmunotherapeutic approachesHLA compatibilityTumor microenvironmentAdult patientsImmunotherapyCombat cancerTumorMalignancyThiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma
Zhang X, Gao Y, Tang K, Li Z, Halberstam A, Zhou L, Perry R. Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma. AJP Endocrinology And Metabolism 2024, 326: e341-e350. PMID: 38294697, PMCID: PMC11901343, DOI: 10.1152/ajpendo.00346.2023.Peer-Reviewed Original ResearchPD-1 expressionCD8+ T cellsT cell exhaustionPD-1T cellsImmunotherapy efficacyAnti-programmed cell death protein 1Tumor-infiltrating CD8+ T cellsAnti-PD-1 monoclonal antibodyAnti-PD-1 responseAnti-PD-1 treatmentCell death protein 1Enhance immunotherapy efficacyEnhance immunotherapy responseImprove immunotherapy efficacyEfficacy of immunotherapyMurine melanoma modelTumor-bearing miceExpression of peroxisome proliferator-activated receptor gammaOverall survival timePeroxisome proliferator-activated receptor gammaEffect of obesityProliferator-activated receptor gammaHuman T cellsTreated in vitro
2023
Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages
Ren P, Hu Y, Peng L, Yang L, Suzuki K, Fang Z, Bai M, Zhou L, Feng Y, Zou Y, Xiong Y, Chen S. Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages. Signal Transduction And Targeted Therapy 2023, 8: 281. PMID: 37518189, PMCID: PMC10387464, DOI: 10.1038/s41392-023-01509-1.Peer-Reviewed Original ResearchApplications of CRISPR technology in cellular immunotherapy
Zhou X, Renauer P, Zhou L, Fang S, Chen S. Applications of CRISPR technology in cellular immunotherapy. Immunological Reviews 2023, 320: 199-216. PMID: 37449673, PMCID: PMC10787818, DOI: 10.1111/imr.13241.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPooled screening with next-generation gene editing tools
Liqun Zhou, Luojia Yang, Yanzhi Feng, Sidi Chen, Pooled screening with next-generation gene editing tools, Current Opinion in Biomedical Engineering, 2023, 100479, ISSN 2468-4511, https://doi.org/10.1016/j.cobme.2023.100479.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2022
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Mao T, Israelow B, Peña-Hernández MA, Suberi A, Zhou L, Luyten S, Reschke M, Dong H, Homer RJ, Saltzman WM, Iwasaki A. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 2022, 378: eabo2523. PMID: 36302057, PMCID: PMC9798903, DOI: 10.1126/science.abo2523.Peer-Reviewed Original ResearchConceptsRespiratory mucosaSystemic immunityLethal SARS-CoV-2 infectionAcute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemicSARS-CoV-2 infectionProtective mucosal immunityCross-reactive immunityT cell responsesCoronavirus 2 pandemicPrimary vaccinationParenteral vaccinesMucosal immunityVaccine strategiesRespiratory tractImmunoglobulin AMemory BImmune memoryPartial immunityCell responsesPoor immunityImmunitySpike proteinMucosaVaccineHeterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Fang Z, Peng L, Lucas C, Lin Q, Zhou L, Yang L, Feng Y, Ren P, Renauer PA, Monteiro VS, Hahn AM, Park JJ, Zhou X, Grubaugh N, Wilen C, Chen S. Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2. Cell Discovery 2022, 8: 69. PMID: 35853867, PMCID: PMC9295082, DOI: 10.1038/s41421-022-00435-w.Peer-Reviewed Original Research
2021
Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors
Liu Y, Liu G, Wang J, Zheng ZY, Jia L, Rui W, Huang D, Zhou ZX, Zhou L, Wu X, Lin S, Zhao X, Lin X. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Science Translational Medicine 2021, 13 PMID: 33762437, DOI: 10.1126/scitranslmed.abb5191.Peer-Reviewed Original ResearchConceptsCAR T cellsT cell receptorSolid tumorsChimeric antigen receptor T-cell therapyMultiple solid tumor modelsRefractory solid tumorsT-cell therapyDurable disease controlHigh response rateSynthetic T cell receptorsB-cell malignanciesHigh antigen sensitivitySolid tumor modelsAntigen recognition domainClinical benefitAntigen stimulationTumor relapseLimited efficacyAntigen sensitivityAntitumor effectsCell malignanciesResponse rateNotable toxicityTumor modelDisease control
Academic Achievements & Community Involvement
News & Links
Get In Touch
Contacts
Email